ClinicalTrials.gg
Active, not recruitingNCT06879717PULMO-01Updated Jan 16, 2026

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients

A Phase 1/2 interventional study of roginolisib and Dostarlimab in Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Advanced Non Squamous NSCLC, sponsored by iOnctura. Active, not recruiting at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by iOnctura · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 3 of them phase 3. Docetaxel · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
103rd of 188
45 · median 50
Started
2025
with 4 others
Phase 1/2
16 of 198
1 open now
Primary completion
2027-01
later than 12 of 19 live
Registered
192nd of 198
by date

Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, this one is the 103rd largest by planned enrollment of the 188 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 in phase 1/2, reaches primary completion later than 12 of the 19 other live ones, and was the 192nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn how roginolisib works in combination with dostarlimab with or without docetaxel in adult patients with advanced non small-cell lung cancer. The main questions it aims to answer are:

To compare across the treatment arms the proportion of patients with a reduction in Treg cells To evaluate the safety and tolerability of roginolisib plus dostarlimab, with or without docetaxel

Read the detailed description

A Phase I/IIa open-label, randomised study of oral roginolisib (IOA-244 [roginolisib hemi-fumarate]) in combination with dostarlimab with or without docetaxel in Advanced Non small-cell lung cancer (NSCLC) patients.

This study will enrol approximately 45 male and female patients aged over 18 years with advanced NSLCL who have process on standard of care immune checkpoint therapy and platinum doublet chemotherapy or standard immunotherapy without chemotherapy. The disease must be measurable (i.e., at least 1 measurable lesion) as per RECIST v1.1 by Computerised Tomography (CT) scan or Magnetic Resonance Imaging (MRI).

03

Conditions studied

  • Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  • Advanced Non Squamous NSCLC

Keywords

  • Advanced non-squamous Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 years of age inclusive, at the time of signing the .
  2. Capable of giving signed informed consent, which includes compliance with the requirements of this protocol.
  3. (ECOG) performance status of 0 to 1.
  4. or cytologically confirmed stage IIIb/IV or recurrent non-squamous NSCLC.
  5. Have per v1.1 as determined by the investigator. Tumour lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  6. Documented radiographic disease progression on or after prior anti-PD(L)1 therapy and platinum chemotherapy or after standard immunotherapy without chemotherapy in accordance with standard of care.
  7. Male or female patients of must be willing to use highly effective forms of (refer to APPENDIX 3 for details on highly effective methods of contraception and definitions of women of childbearing potential [WOCBP]and of fertile men):

    1. Women of childbearing potential (WOCBP) must have a negative serum test as per local guidelines during screening and EOT and agree to have regular urine pregnancy testing throughout the study. WOCBP must agree to use a highly effective method of contraception and refrain from donating eggs throughout the study and until 4 months after last dose of IMP;
    2. Male patients must agree to use barrier method of contraception [condom plus spermicide] from screening through Safety Follow-up visit, at least 1 month after the last dose of IMP. Men should refrain from donating sperm from the day of first dose of IMP, throughout the study and until 3 months after last dose of IMP. Men with partners of child-bearing potential must also be willing to ensure that their partner uses a highly effective method of contraception for the same duration. Men with pregnant or lactating partners should be advised to use barrier method contraception (e.g., condom plus spermicidal gel) to prevent exposure to the foetus or neonate.

Exclusion criteria

Exclusion Criteria:

  1. Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications.
  2. or cytologically confirmed squamous NSCLC.
  3. Previously treated with dostarlimab or docetaxel.
  4. Have prior significant medical history and AEs:

    1. History of a prior Grade 3 or 4 immune-related AE (irAE) or any grade ocular irAE from prior immunotherapy which did not respond to therapy or resolved with treatment interruptions and returned to at least Grade 1; immunemediated severe neurologic events of any grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, Guillain-Barré Syndrome, or transverse myelitis), exfoliative dermatitis of any grade (SJS, TENS, or DRESS syndrome), or myocarditis of any grade.
    2. Have not recovered from toxic effect(s) of prior therapy to ≤ Grade 1, other than alopecia or fatigue or neuropathy which must be ≤ Grade 2.
    3. Active process (e.g., rheumatoid arthritis, moderate or severe psoriasis, multiple sclerosis, inflammatory bowel disease, immune colitis) that has required systemic treatment in the past 2 years. Replacement therapy (e.g.thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
    4. Known active and/or carcinomatous meningitis.

    i. Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks before the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not required steroids for at least 7 days before study treatment. e. History of long syndrome or history or presence of an abnormal that, in the Investigator's opinion, is . Screening QTc interval > 450 milliseconds is excluded (corrected by Fridericia). In the event that a single QTc is > 450 milliseconds, the patient may enrol if the average QTc for the 3 ECGs is \< 450 milliseconds. For patients with an intraventricular conduction delay (QRS interval > 120 msec), the JTc interval may be used in place of the QTc with Sponsor approval. The JTc must be \< 340 milliseconds if JTc is used in place of the QTc. Patients with left bundle branch block are excluded.

    f. History of or current risk factor for torsade de pointes (e.g., heart failure, hypokalaemia, or a family history of long QT syndrome). g. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (\< 6 months prior to enrolment), myocardial infarction (\< 6 months prior to enrolment), unstable angina, congestive heart failure (≥ Classification Class II), or any of the following (\<6 months prior to enrolment): acute coronary syndromes, coronary angioplasty or bypass grafting, serious cardiac arrhythmia requiring medication including second degree (Type 2) or third degree AV block, cardiomyopathy, pericarditis or myocarditis.

    h. Any history of interstitial lung disease or pneumonitis. i. History of allogenic stem cell transplantation or organ transplantation. j. Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, oesophageal/ gastric varices, persistent jaundice k. Women who are pregnant or breastfeeding l. Active infection requiring systemic therapy. m. Patients with active requiring concurrent intervention or previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, endometrial, cervical/dysplasia, melanoma or breast) unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required during the study period.

    n. Any serious or uncontrolled medical disorder or active infection that, in the opinion of the Investigator, may increase the risk associated with study participation, study drug administration, or would impair the ability of the patient to receive protocol therapy.

  5. Treatment with anticancer medications, drugs, surgery and/or radiation within the following interval before the first administration of study drug:

    1. \<90 days for prior taxane.
    2. \<14 days for chemotherapy, targeted small-molecule therapy, surgical resection of lesions or radiation therapy (prior palliative radiotherapy must have been completed at least 14 days prior to study drug administration). Patients must also not require corticosteroids and must have recovered from pneumonitis as a result of treatment and show no evidence of pneumonitis for at least 1 month. A 1-week is permitted for palliative radiation to non-CNS disease with Sponsor approval. Note: The use of denosumab is permitted.
    3. \< 14 days for a prior PD1 pathway-targeted agent.
    4. \< 28 days for prior monoclonal antibody used for anticancer therapy with the exception of PD1 pathway-targeted agents.
    5. \< 28 days or 5 half-lives (whichever is longer) before the first dose for all other investigational study drugs or devices. For investigational agents with long halflives (e.g., > 5 days), enrolment before the fifth half-life requires Medical Monitor approval.
    6. Radiotherapy -At least 6 weeks from prior radioisotope therapy. Note: Investigational agents that are not designed as antineoplastic treatment but used in combination with standard therapies are allowed.
  6. Receiving an immune-suppressive based treatment for any reason (including chronic use of systemic corticosteroid at doses > 10 mg/day prednisone equivalent) within 14 days prior to the first dose of study treatment. Use of inhaled or topical steroids (including but not limited to creams or intra-articular injection) or brief corticosteroid use for radiographic procedures or systemic corticosteroids ≤ 10 mg is permitted.
  7. Have received a within 30 days of planned start of study therapy while on trial. With regards to other type of vaccines, including SARS-Co2 vaccines, are allowed.
  8. Known allergy or reaction to any component of either study drugs or formulation components.
  9. Known alcohol or other substance abuse.
  10. Laboratory and medical history parameters not within Protocol-defined range. Cycle 1 Day 1 laboratory assessments for the determination of eligibility do not need to be performed if the screening laboratory assessments were performed within 7 days of Cycle 1 Day 1. If the screening laboratory assessments were performed more than 7 days before Cycle 1 Day 1, then the haematology and serum chemistry laboratory results must be confirmed up to 3 days before treatment initiation on Cycle 1 Day 1.

    1. \< 1.5 × 109/L.
    2. count \< 100 × 109/L.
    3. \< 9 g/dL (transfusion is acceptable to meet this criterion).
    4. Serum creatinine ≥ 1.5 × institutional (ULN) or measured or calculated (CrCl) ( can also be used in place of creatinine or CrCl) \< 50 mL/min for patients with creatinine levels > 1.5 × institutional ULN.
    5. (AST) or ALT ≥ 2.5 × ULN in the absence of hepatic or ≥ 5 × ULN with hepatic metastases at screening.
    6. Total ≥ 1.2 × ULN are excluded unless direct bilirubin is ≤ ULN. If there is no institutional ULN, then direct bilirubin must be \< 40% of total bilirubin to be eligible (except patients with Gilbert syndrome, who must have total bilirubin \< 51.3 μmol/L).
    7. or prothrombin time (PT) > 1.5 × ULN.
    8. Activated partial thromboplastin time (aPTT) > 1.5 × ULN.
    9. Evidence of acute infection of virus (HBV), (for example: positive for HBsAg, anti-HBc, IgM anti-HBc and negative for anti-HBs), virus (HCV) (for example: HCV antibody reactive; HCV RNA detected) and (HIV). Patients who are on stable antiviral therapy for their viral infection of hepatitis (e.g., HBV, HCV) or HIV (i.e., for at least 12 months) and willing to remain on these during and for 6 months after end of study treatment, and/or asymptomatic are eligible for the study.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Arm 1: Roginolisib + dostarlimab + docetaxel

    IOA-244 80 mg (corresponding to 72 mg roginolisib) once daily oral dosing on a 21-day cycle. Dostarlimab: 500 mg administered as IV infusion over 30 minutes on Day 1 of every 21-day cycle to a maximum of 35 cycles. Docetaxel: 75 mg/m2 administered over 1 hour as IV infusion on Day 1 of every 21-day cycle.

    Drug: roginolisib · Drug: Dostarlimab · Drug: Docetaxel

  • Experimental
    Arm 2: Roginolisib + dostarlimab

    IOA-244 80 mg (corresponding to 72 mg roginolisib) once daily oral dosing on a 21-day cycle. Dostarlimab: 500 mg administered as IV infusion over 30 minutes on Day 1 of every 21-day cycle to a maximum of 35 cycles.

    Drug: roginolisib · Drug: Dostarlimab

  • Active comparator
    Arm 3: Dostarlimab + docetaxel

    Dostarlimab: 500 mg administered as IV infusion over 30 minutes on Day 1 of every 21-day cycle to a maximum of 35 cycles. Docetaxel: 75 mg/m2 administered over 1 hour as IV infusion on Day 1 of every 21-day cycle.

    Drug: Dostarlimab · Drug: Docetaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE V5

    Safety measured by AEs

    Time frame: On Day 1 and Day 15 of Cycle 1; Day 1 of Cycle 2 onwards. Each cycle is 21 days

  2. To compare across treatment arms the proportion of patients with a reduction in peripheral blood Tregs (for example as defined by CD4+CD25+CD127- expression)

    Change from baseline of at least 50% by Day 42 as assessed by mass cytometry (cytometry by time of flight, CyTOF)

    Time frame: On Day 1 of each Cycle. Cycle length is 21 days

  3. Number of Participants With changes in laboratory parameters

    Measures by chemistry and haematology laboratory parameters

    Time frame: On Day 1and Day 15 of Cycle 1; Day 1 of Cycle 2 onwards. Each cycle is 21 days

  4. Number of Participants with Changes in ECG from baseline

    Measured by 12 Lead ECG

    Time frame: On Day 1 and Day 15 of Cycle 1; Day 1 of Cycle 2 onwards. Each cycle is 21 days

  5. Number of Participants With Change on Physical Examination from Baseline

    Measured by physical examination

    Time frame: On Day 1and Day 15 of Cycle 1; Day 1 of Cycle 2 onwards. Each cycle is 21 days

Secondary outcomes

  1. To further evaluate immune cell subsets in peripheral blood following treatment with roginolisib when given in combination with dostarlimab, and with/without docetaxel

    Change from baseline in immune related signatures as assessed by mass cytometry (expanded analyses using the same sample used for the primary endpoint)

    Time frame: On Day 1 of each cycle up to 36 weeks. Each cycle is 21 days

  2. To evaluate preliminary signs of clinical efficacy of roginolisib when given in combination with dostarlimab, and with/without docetaxel

    Objective Response Rate (ORR) per RECIST v1.1 as assessed by the investigator

    Time frame: Every 6 weeks whilst on treatment anticipated to be 36 weeks

  3. To evaluate preliminary signs of clinical efficacy of roginolisib when given in combination with dostarlimab, and with/without docetaxel

    Duration of response (DOR) per RECIST v1.1 as assessed by the investigator

    Time frame: Every 6 weeks whilst on treatment anticipated to be 36 weeks

  4. To evaluate preliminary signs of clinical efficacy of roginolisib when given in combination with dostarlimab, and with/without docetaxel

    Disease Control Rate (DCR) per RECIST v1.1 as assessed by the investigator

    Time frame: Every 6 weeks whilst on treatment anticipated to be 36 weeks

  5. To evaluate preliminary signs of clinical efficacy of roginolisib when given in combination with dostarlimab, and with/without docetaxel

    Clinical Benefit Rate (CBR) per RECIST v1.1 as assessed by the investigator

    Time frame: Every 6 weeks whilst on treatment anticipated to be 36 weeks

  6. To evaluate preliminary signs of clinical efficacy of roginolisib when given in combination with dostarlimab, and with/without docetaxel

    Progression free survival (PFS) per RECIST v1.1 as assessed by the investigator

    Time frame: Every 6 weeks whilst on treatment anticipated to be 36 weeks

  7. To evaluate preliminary signs of clinical efficacy of roginolisib when given in combination with dostarlimab, and with/without docetaxel

    Overall survival (OS)

    Time frame: Every 12 weeks after safety follow-up until their death or end of study

  8. Pharmacokinetic (PK) concentration of roginolisib when given in combination with dostarlimab, and with/without docetaxel

    Plasma concentrations of roginolisib

    Time frame: Day 1 of each whilst on treatment anticipated to be 36 weeks. Cycle length is 21 days

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jan 2027, 21 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 21 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 17, 2025
StartActual
Apr 22, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2028
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06879717
Lead sponsor
iOnctura
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Apr 22, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jan 16, 2026

Study contacts

Michael Lahn, MD
study director · iOnctura

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Roginolisib · Docetaxel

Start the discussion